U.S. markets closed
  • S&P 500

    4,387.11
    -8.15 (-0.19%)
     
  • Dow 30

    34,837.54
    -97.93 (-0.28%)
     
  • Nasdaq

    14,680.95
    +8.27 (+0.06%)
     
  • Russell 2000

    2,220.25
    -6.00 (-0.27%)
     
  • Crude Oil

    71.39
    -2.56 (-3.46%)
     
  • Gold

    1,816.80
    -0.40 (-0.02%)
     
  • Silver

    25.47
    -0.08 (-0.30%)
     
  • EUR/USD

    1.1874
    -0.0001 (-0.01%)
     
  • 10-Yr Bond

    1.1740
    -0.0650 (-5.25%)
     
  • GBP/USD

    1.3890
    -0.0016 (-0.12%)
     
  • USD/JPY

    109.3030
    -0.3120 (-0.28%)
     
  • BTC-USD

    39,206.23
    -2,099.80 (-5.08%)
     
  • CMC Crypto 200

    958.05
    -2.84 (-0.30%)
     
  • FTSE 100

    7,081.72
    +49.42 (+0.70%)
     
  • Nikkei 225

    27,781.02
    +497.43 (+1.82%)
     

Albireo's Rare Liver Disease Drug Bylvay Scores Back To Back Approvals In Europe, US

·1 min read
  • Just a day after European approval, Albireo Pharma Inc (NASDAQ: ALBO) has received FDA approval for Bylvay (odevixibat), the first drug approved to treat pruritus in all subtypes of progressive familial intrahepatic cholestasis (PFIC).

  • PFIC afflicts children with severe, progressive liver disease.

  • The FDA approved Bylvay based on phase 3 trials showing that the drug can help ease pruritus and reduce serum bile acids. It isn't yet known whether it can reduce the need for liver transplants.

  • The approval marks a high point for the company, spun out of AstraZeneca PLC (NASDAQ: AZN) way back in 2008.

  • Since then, it went public through a reverse merger and was later forced to shed its nonalcoholic steatohepatitis (NASH) candidate. It failed to achieve proof-of-concept for key NASH measures.

  • FDA issued a Rare Pediatric Disease Priority Review Voucher (PRV), which the company plans to monetize.

  • It had cash and cash equivalents of $186.3 million as of June 30 and anticipates the 2021 operating cash burn of $130 million to $135 million.

  • Excluding any proceeds from the planned sale of the PRV, the company believes that its cash balance will fund its expenses into 2023.

  • Albireo is kicking off an "immediate" launch.

  • Price Action: ALBO shares are up 3.41% at $35.50 during the premarket session on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.